Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of XZ120 in Patients With Malignant Tumors in a Phase Ⅰ Clinical Trial

NCT06206915 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT06206915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06206915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of XZ120 in Patients With Malignant Tumors in a Phase Ⅰ Clinical Trial
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 1, 2024
Completion date
February 1, 2027
Enrollment
123 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies